• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

161058-83-9 (NU2058)

1

Identification

NU2058 NU2058
Name NU2058
Formula C12H17N5O
MW 247.3
CAS No. 161058-83-9
EINECS
Smiles NC1=NC(OCC2CCCCC2)=C3NC=NC3=N1
Synonyms NU-2058;O6-(Cyclohexylmethyl)guanine; 6-(cyclohexylmethoxy)-7H-purin-2-amine
InChI InChI=1S/C12H17N5O/c13-12-16-10-9(14-7-15-10)11(17-12)18-6-8-4-2-1-3-5-8/h7-8H,1-6H2,(H3,13,14,15,16,17)
2

Introduction

NU2058 is a guanine-based CDK inhibitor with IC50 of 17 μM and 26 μM for CDK2 and CDK1. IC50 value: 17μM (CDK2), 26μM (CDK1) Target: CDK in vitro: NU2058 is a competitive inhibitor of CDK2 with respect to ATP (Ki value CDK2, 12 3 μM) that binds in the ATP binding pocket in a different orientation from other purine-based inhibitors, including olomoucine and roscovotine.

Background Information

NU2058 is a competitive inhibitor of CDK2 with respect to ATP (Ki value CDK2, 12 3 μM) that binds in the ATP binding pocket in a different orientation from other purine-based inhibitors, including olomoucine and roscovotine. NU2058 is the lead compound in a structure-based drug discovery program to develop more potent and selective CDK inhibitors. ......by AbMole BioScience
NU2058 is a guanine-based CDK inhibitor with IC50 of 17 uM and 26 uM for CDK2 and CDK1. ......by AdooQ BioScience, LLC
NU2058 is a potent CDK inhibitor. which has CDK2 IC(50)=17 microM and CDK1 IC(50)=26 microM. ......by BOC Sciences
NU2058 is a potent CDK inhibitor that has CDK2 IC(50)=17 microM and CDK1 IC(50)=26 microM. ......by MedKoo Biosciences, Inc.
An ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 5 uM and 12 uM respectively; inhibits human tumor cells with a mean GI50 of 13±7 uM; reduces CDK2-mediated phosphorylation of pRb, E2F transcriptional activity and proliferatio in both anti-estrogen-sensitive and resistant cells; also inhibits DNA topoisomerase II ATPase activity (IC50=300 uM). ......by ProbeChem
NU2058 is an inhibitor of CDK2 with IC50 value of 17 μM in an isolated enzyme assay. It also potentiates melphalan (DMF 2.3), and monohydroxymelphalan (1.7), but not temozolomide or ionising radiation. ......by Selleck Chemicals LLC
Cyclin-dependent kinase (cdk) 1 and cdk2 inhibitor (Ki values are 5 and 12 μM respectively). Inhibits growth of human tumor cells in vitro (mean GI50 = 13 μM). Also inhibits DNA topoisomerase II ATPase activity (IC50 = 300 μM). ......by Tocris Bioscience Inc.
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance:White to off-white Solid EBNumber:EB000068642

Storage condition

4°C by MedChemexpress Co., Ltd.
Store at +4°C by Tocris Bioscience Inc.

Solubility

10 mM in DMSO by CHEMSCENE, LLC
10 mM in DMSO by MedChemexpress Co., Ltd.
Soluble to 100 mM in DMSO and to 10 mM in ethanol by Tocris Bioscience Inc.
5

Mechanism and Indication

Signaling Pathways Cell Cycle/DNA Damage
Target CDK
Research Area Cancer
Indications
6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
NU2058 - Not Found
NU2058 - No Development Reported
7

Safety Data of NU2058

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
AbMole BioScience USA
AdooQ BioScience, LLC USA
Ark Pharm, Inc. USA
BOC Sciences
Biochempartner Co., Ltd China
CHEMSCENE, LLC 5mg/USD84();10mg/USD144() USA
Cayman Chemical Company USA
MedChemexpress Co., Ltd. 5mg/USD84();10mg/USD144() USA
MedKoo Biosciences, Inc. USA
ProbeChem
Selleck Chemicals LLC USA
Shanghai Haoyuan Chemexpress Co., Ltd. 5mg/USD84();10mg/USD144() China
Tocris Bioscience Inc. USA
10

Related Products

Other Forms of 161058-83-9

Name CAS No Formula MW

Recommended Compounds in CDK

Name CAS No Formula MW
LY2857785 1619903-54-6 C26H36N6O 448.6
THZ2 1604810-84-5 C31H28ClN7O2 566.0527
Palbociclib (isethionate) 827022-33-3 C26H35N7O6S 573.66
CDK9-IN-6 1391855-95-0 C27H37ClN6O2 513.07468
ML167 1285702-20-6 C19H17N3O3 335.36
AMG 925 1401033-86-0 C26H29N7O2 471.55
LDC000067 1073485-20-7 C18H18N4O3S 370.43
LEE011 (succinate hydrate) 1374639-79-8 C27H38N8O6X 570.64
LEE011 (succinate) 1374639-75-4 C27H36N8O5 552.63
LEE011 (hydrochloride) 1211443-80-9 C23H31ClN8O 471.0
LEE011 1211441-98-3 C23H30N8O 434.54
WHI-P180 (hydrochloride) 153437-55-9 C16H16ClN3O3 333.77
Wogonin 632-85-9 C16H12O5 284.26
1-NM-PP1 221244-14-0 C20H21N5 331.41
WHI-P180 211555-08-7 C16H15N3O3 297.31
THZ1 1604810-83-4 C31H28ClN7O2 566.05
Senexin A 1366002-50-7 C17H14N4 274.32
CDK4-IN-1 1256963-02-6 C22H29ClN8 440.97
Palbociclib (hydrochloride) 827022-32-2 C24H30ClN7O2 483.99
Purvalanol B 212844-54-7 C20H25ClN6O3 432.9

Recommended Compounds in Same Indication

Name CAS No Formula MW
11

Route of Synthesis

12

References

13

More Information

NU2058

Tags: buy 161058-83-9 IC50 | 161058-83-9 price | 161058-83-9 cost | 161058-83-9 solubility | 161058-83-9 purchase | 161058-83-9 manufacturer | 161058-83-9 research buy | 161058-83-9 order | 161058-83-9 MSDS | 161058-83-9 chemical structure | 161058-83-9 Storage condition | 161058-83-9 molecular weight | 161058-83-9 mw | 161058-83-9 datasheet | 161058-83-9 supplier | 161058-83-9 cell line | 161058-83-9 NMR | 161058-83-9 MS | 161058-83-9 IR | 161058-83-9 solubility | 161058-83-9 Safe information | 161058-83-9 Qc and Spectral Information | 161058-83-9 Clinical Information | 161058-83-9 Clinical Trial | 161058-83-9 Route of Synthesis | 161058-83-9 storage condition | 161058-83-9 diseases and conditions | 161058-83-9 flash point | 161058-83-9 boiling point | 161058-83-9 melting point | 161058-83-9 storage condition | 161058-83-9 brand